MindMed works to improve patient outcomes through a pipeline of novel drug candidates, focusing on the therapeutic potential of psychedelics and other compounds to address unmet needs in psychiatry, addiction, pain, and neurology.

MindMed

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

CO:MINDMED

MindMed

Last Close

7.09

22/11 21:00

Market Cap

500.56M

Beta: -

Volume Today

1.02M

Avg: -

Analysis Not Available